Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 8, 2025BloodOpen Access

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJeff P. SharmanMEMiklós EgyedWJWojciech Jurczak

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sharman et al. (2025) studied this question.

synapsesocial.com/papers/6a128f75ea48cb855a3515dchttps://doi.org/10.1182/blood.2024024476
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia2020 · 80 citations
  2. 2Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial2023 · 138 citations
  3. 3iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL2018 · 1,757 citations
  4. 4Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia2015 · 902 citations
  5. 5Characterization of real‐world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center2021 · 13 citations